The University of Virginia is conducting a clinical research study for patients who are adults ages 18 and over, and have non-muscle invasive bladder cancer (NMIBC) and they either have not had Bacillus Calmette-Guerin (BCG) therapy or have not responded well to BCG. The purpose of this study is to evaluate an investigational drug, EG-70. The safety and effects of the investigational drug will be assessed for this study.
Participation includes a screening period, a 144-week treatment period, which consists of at least one 12-week treatment cycle and up to 4 of these 12-week treatment cycles over a year. This also includes a longer-term follow-up via a clinic visit or a phone call every 3 months to keep track of how you’re doing after the end of treatment. During the treatment period, EG-70 will be inserted directly into your bladder via a catheter. This investigational treatment will occur at least 4 times during each 12-week cycle of the treatment period. Study-specific tests will be provided at no cost to you.
Additional information can be found here: https://classic.clinicaltrials.gov/ct2/show/NCT04752722
Contact= UVACANCERTRIALS@uvahealth.org
You may receive compensation or reimbursement for this study.